mibe pharma

What mibe pharma does

mibe pharma Italia is a privately-held Italian pharmaceutical subsidiary wholly owned by the German pharmaceutical group Dermapharm AG. The company develops and markets over-the-counter medicines and dietary supplements for the Italian consumer market, distributed exclusively through Italian pharmacies with pharmacist consultation. Its commercial portfolio comprises four branded products: Keltican FORTE (a UTP/uridine-based supplement for peripheral nerve regeneration), Vitenson Daily (a 2,000 IU vitamin D3 supplement for immune, bone and muscle health), Phalanx (an SOP cutaneous spray for alopecia in men and women, authorized October 2024), and Fungilak (an amorolfine-based medicated nail lacquer for onychomycosis, also authorized October 2024). The product mix blends two dietary supplements in capsule/tablet form with two pharmacist-dispensed SOP medicines, all formulated to be free from common allergens such as gluten and lactose.

The company operates with a sales-and-marketing-only footprint in Italy, with a registered office in Bolzano and operational headquarters in Milan (Via Ampère 56, 20131). Manufacturing and broader R&D are not described as in-house at the Italian entity level; instead the subsidiary is positioned as the commercial arm responsible for Italian pharmacy distribution, regulated pharmacovigilance (24/7 contact line), and brand stewardship for the four trademarks. Products are classified as SOP (medicinali senza obbligo di prescrizione) where applicable and can be dispensed only by pharmacists, embedding the pharmacist channel into the regulatory and commercial model.

Revenue mechanics are one-time sales of OTC products through pharmacy resellers. No pricing is publicly disclosed, no software or data platform underpins the business, and there are no named institutional customers or enterprise contracts — the customer base is long-tail Italian consumers. The company sits within a broader Dermapharm AG holding structure that provides corporate governance, parent branding (mibe.dermapharm.com), and shared back-office infrastructure, which gives the subsidiary scale advantages but also constrains its ability to act independently of the German parent.

Name

mibe pharma

Legal name

mibe pharma Italia

Website

https://mibepharmaitalia.dermapharm.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

OTC Pharmaceuticals and Dietary Supplements

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity) (CRADAGAE)

akta.pro secondary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Pharmaceutical products
• OTC medicines
• Dietary supplements
• Dermatological treatments
• Nerve health supplements

Headquarters

HQ city

Milan

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical and OTC Product Sales: Revenue is generated through the sale of over-the-counter medicines and dietary supplements distributed via pharmacy channels in Italy. Products include prescription-free medicines (SOP - medicinali senza obbligo di prescrizione) and food supplements sold directly through pharmacists.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

mibe pharma develops, markets and distributes a focused portfolio of over-the-counter pharmaceutical products and dietary supplements in Italy. The portfolio comprises two prescription-free medicinal products (Phalanx cutaneous spray for alopecia and Fungilak amorolfine medicated nail polish for onychomycosis) and two dietary supplements (Keltican FORTE capsules supporting peripheral nerve regeneration and Vitenson Daily 2,000 IU vitamin D3 tablets). All products are dispensed exclusively through Italian pharmacies.

Product overview

mibe pharma is an Italian subsidiary of Dermapharm AG, operating as a pharmaceutical and dietary supplement company with a portfolio of four distinct branded products. The portfolio includes two prescription-free medicinal products (Phalanx® for alopecia treatment and Fungilak® for nail fungus) and two dietary supplements (Keltican® FORTE for nerve regeneration and Vitenson® Daily for vitamin D3 supplementation). The product range addresses dermatological, neurological, and general wellness needs through both medicinal and nutraceutical offerings.

Differentiator

Problem solved

Functional benefit

Brands

• Keltican® Forte: Capsule apribili for favouring physiological regeneration of peripheral nerves. Gluten-free, lactose-free, gelatin-free, vegan.
• Vitenson® Daily
• Phalanx®
• Fungilak®

Products and services

• Keltican FORTE

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Dermapharm AGcoreStrategic or Co-development Partnermibe pharma Italia is a wholly-owned subsidiary of Dermapharm AG, a German pharmaceutical company. The subsidiary operates as part of the Dermapharm holding structure, benefiting from the parent company's pharmaceutical manufacturing expertise and regulatory capabilities. Dermapharm AG serves as the strategic parent entity providing corporate governance and operational support.

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Menarini: Major Italian pharmaceutical group with consumer health and OTC products distributed via Italian pharmacies. Operates in the same regulatory environment with a comparable branded OTC model.
• Bayer Consumer Health Italy: Italian consumer health arm of Bayer, distributing branded OTC and self-care products through Italian pharmacies. Comparable as an established OTC player in the same pharmacy distribution channel.
• Chiesi Farmaceutici: Italian-headquartered pharmaceutical company with consumer health and OTC offerings alongside its prescription business. Comparable as an Italian pharma operating with branded products in pharmacy channels.
• Angelini Pharma: Italian pharmaceutical group with a substantial OTC and consumer health portfolio sold through Italian pharmacies. Comparable as a domestically-rooted pharma company operating in the same pharmacy channel with similar product categories.
• Dompé: Italian specialty pharmaceutical company with OTC consumer health products including dermatology and self-care lines. Comparable in operating from Italy with branded specialty pharma products sold via pharmacies.
• Alfasigma: Italian pharmaceutical company with a meaningful OTC and self-medication portfolio distributed through pharmacies. Comparable as an Italian pharma player with branded OTC medicines and supplements.
• Recordati: Italian pharmaceutical group with a consumer health division covering OTC and self-care products. Comparable as an Italian-headquartered pharma with branded pharmacy products, though at materially larger scale.
• Sanofi Consumer Healthcare Italy: Italian operations of Sanofi's consumer healthcare division, distributing leading OTC brands through Italian pharmacies. Comparable as an OTC competitor operating in the same channel with established consumer brands.

Emerging players

• Abiogen Pharma: Italian specialty pharmaceutical company of comparable size, focused on bone, joint, and metabolic health with branded prescription and OTC products. Comparable as a mid-sized Italian specialty pharma operating in similar therapeutic areas.
• Giuliani SpA: Italian consumer health and pharmaceutical company of similar scale, focused on dermatology, gastrointestinal, and self-care products. Comparable as a mid-sized Italian player with branded pharmacy-distributed products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about mibe pharma